While genomic surveillance can play a crucial role in detecting and responding to diseases from influenza to antimicrobial-resistant bacteria, making the case for these investments is not always straightforward.
Complex considerations include rapidly evolving sequencing technologies, varying disease burdens across countries and the challenge of measuring long-term benefits. To help navigate these factors, the authors advocate for a framework that links genomic surveillance to public health priorities using a cost-sensitive approach that can provide real-time and actionable information to decision makers.